1645

#4

FULBRIGHT & JAWORSKI L.L.P.
A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-3271
WWW.FULBRIGHT.COM

RHANSON@FULBRIGHT.COM
DIRECT DIAL: (512) 536-3085
TELEPHONE: (512) 474-5201
FACSIMILE: (512) 536-4598

May 28, 2002

COPY OF PAPERS
ORIGINALLY FILED

CERTIFICATE OF MAILING
37 C.F.R 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:

May 28, 2002
Date

Robert E. Hanson

Commissioner for Patents
Washington, DC 20231

Re: *U.S. Patent Application No. 09/992,556 entitled "INHIBITION OF NF-κB BY TRITERPENE COMPOSITIONS" by Jordan U. Gutterman and Valsala Haridas*
Our Reference: CLFR:009US

Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement, Form PTO-1449, and references (C1-C27).

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10111753/REH.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

Robert E. Hanson
Reg. No. 42,628

REH/cmb
Encl.: as noted

25168182.1

COPY OF PAPERS
ORIGINALLY FILED

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Jordan U. Gutterman
Valsala Haridas

Serial No.: 09/992,556

Filed: November 16, 2001

For: INHIBITION OF NF-κB BY TRITERPENE COMPOSITIONS

Group Art Unit: 1645

Examiner: Unknown

Atty. Dkt. No.: CLFR:009US

RECEIVED
JUN 12 2002
TECH CENTER 1600/2900

CERTIFICATE OF MAILING
37 C.F.R 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:

May 28, 2002
Date

Robert E. Hanson

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10111753/REH.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Robert E. Hanson
Reg. No. 42,628
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: May 28, 2002

Form PTO-1449 (modified)	Atty. Docket No. CLFR:009US	Serial No. 09/992,556
List of Patents and Publications for Applicant's	Applicant Jordan U. Gutterman Valsala Haridas	
INFORMATION DISCLOSURE STATEMENT	Filing Date: November 16, 2001	Group: 1645
(Use several sheets if necessary)		

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 1*

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Akiyama *et al.*, "Genistein, a specific inhibitor of tyrosine-specific protein kinases," *J. Biol. Chem.*, 262:5592-5595, 1987.
	C2	Baeuerle and Baichwal, "NF-kB as a frequent target for immunosuppressive and anti-inflammatory molecules," *Adv. Immunol.*, 65: 111-137, 1997.
	C3	Bantel *et al.*, "Mistletoe lectin activates caspase-8/FLICE independently of death receptor signaling and enhances anticancer drug-induced apoptosis," *Cancer Res.* 59:2083-2090, 1999.
	C4	Beutler *et al.*, "Isolation and characterization of novel cytotoxic saponins from Archidendron ellipticum," *Bioorg. Med. Chem.*, 5:1509-1517, 1997.
	C5	Chen *et al.*, "Structure determination of three saponins from the stem bark of Albizzia julibrissin Durazz," *Yaoxue Xuebao*, 32:110-115, 1997, Abstract (article in Chinese).
	C6	Chen *et al.*, "Studies on the triterpene sapogenins from Albizziae cortex," *Yaoxue Xuebao*, 32:144-147, 1997, Abstract (article in Chinese).
	C7	D'Arcy and Kellett, "Glycyrrhetinic acid," *Br. Med. J.*, 1:647, 1957.
	C8	Frechet *et al.*, "Four triterpenoid saponins from dried roots of *Gypsophila* species," *Phytochemistry*, 30:927-931, 1991.
	C9	Fulda *et al.*, "Betulinic acid triggers CD95 (APO-1/Fas)- and p53-independent apoptosis via activation of caspases in neuroectodermal tumors," *Cancer Res.* 57:4956-4964, 1997.

25119183.1

EXAMINER:	DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. CLFR:009US	Serial No. 09/99[illegible],556
List of Patents and Publications for Applicant's	Applicant Jordan U. Gutterman Valsala Haridas	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Filing Date: November 16, 2001	Group 1645

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 1*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C10	Goodwin *et al.*, "Microglial release of nitric oxide by the synergistic action of beta-amyloid and IFN-gamma," *Brain Research*, 692(1-2):207-214, 1995.
	C11	Hanausek *et al.*, "Avicins, a family of triterpenoid saponins from Acacia victoriae (Bentham), suppress H-ras mutations and aneuploidy in a murine skin carcinogenesis model," *Proc. Natl. Acad. Sci.*, 98:11551-11556, 2001.
	C12	Hantraye *et al.*, "Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons," *Nat. Med.*, 2:1017-1021, 1996.
	C13	Haridas *et al.*, "Avicins, a family of triterpenoid saponins from Acacia victoriae (Bentham), inhibit activation of nuclear factor κB by inhibiting both its nuclear localization and ability to bind DNA," *Proc. Natl Acad. Sci.*, 98:11557-11562, 2001.
	C14	Hooper *et al.*, "Prevention of experimental allergic encephalomyelitis by targeting nitric oxide and peroxynitrite : implications for the treatment of multiple sclerosis," *Proc. Natl. acad. Sci. USA*, 94: 2528-2533, 1997.
	C15	Hostettmann and Marston, *Chemistry and pharmacology of natural products, Saponins*, Cambridge University Press, 18-76, 1995.
	C16	Ikeda *et al.*, "Cytotoxic glycosides from Albizzia julibrissin," *J. Nat. Prod.*, 60:102-107, 1997.
	C17	Inoue *et al.*, "Inhibitory effect of glycyrrhetinic acid derivatives on lipoxygenase and prostaglandin synthetase," *Chem. Pharm. Bull.*, 34(2):897-901, 1986.
	C18	Kim *et al.*, "Inhibition of mouse ear edema by steroidal and triterpenoid saponins," *Archives of Pharmacal Research*, 22(3):313-316, 1999.
	C19	Ma *et al.*, "NMR determination of the structure of Julibroside J1," *Carbohydr. Res.*, 281:35-46, 1996.
	C20	Ohshima and Bartsch, "Chronic infections and inflammatory processes as cancer risk factors : possible role of nitric oxide in carcinogenesis," *Mutat. Res.*, 305:253-264, 1994.
	C21	Prehn, "Regeneration versus neoplastic growth," *Carcinogenesis*, 18(8):1439-1444, 1997.
	C22	Schuh *et al.*, "Obligatory wounding requirement for tumorigenesis in v-*jun* transgenic mice," *Nature*, 346:756-760, 1990.

25119183.1

EXAMINER:	DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. CLFR:009US	Serial No. 09/993,556
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant Jordan U. Gutterman Valsala Haridas	
	Filing Date: November 16, 2001	Group: 1645

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 1*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C23	Sieweke *et al.*, "Mediation of wound-related rous sarcoma virus tumorigenesis by TGF-β," *Science*, 248:1656-1660, 1990.
	C24	Singh *et al.*, "Anti-inflammatory activity of oleanolic acid in rats and mice," *J. Pharm. Pharmacol*, 44:456-458, 1992.
	C25	Sporn and Roberts, "Peptide growth factors and inflammation, tissue repair and cancer," *J. Clin. Invest.*, 78:329-332, 1986.
	C26	Takahashi *et al.*, "Increased expression of inducible and endothelial constitutive nitric oxide synthases in rat colon tumors induced by azoxymethane," *Cancer Research*, 57(7):1233-1237, 1997.
	C27	Zou *et al.*, "A new isomer of Julibroside J2 from Albizia julibrissin," *J. Asian Nat. Prod. Res.*, 1:59-66, 1998, Abstract.
	C28	Co pending Patent Application Number 09/314,691, filed May 19, 1999.

COPY OF PAPERS
ORIGINALLY FILED

25119183.1

EXAMINER:	DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.